The immunotherapy technology developer has set a $230m target for an initial public offering that would offer exits to LabCorp, Illumina, Celgene and BD Biosciences.

US-based drug discovery technology developer Adaptive Biotechnologies has filed for a $230m initial public offering that would enable investors companies Celgene, Illumina, LabCorp and BD Biosciences to exit. Formerly known as Adaptive TCR, Adaptive has built a clinical immunomics database that could form the basis of treatments for cancer, autoimmune disorders and infectious diseases that…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.